Affimed (NASDAQ:AFMD) Rating Lowered to Hold at Cantor Fitzgerald

Affimed (NASDAQ:AFMD) was downgraded by investment analysts at Cantor Fitzgerald from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

AFMD has been the subject of a number of other research reports. Leerink Partners reissued a “market perform” rating and issued a $0.39 price objective (down previously from $5.00) on shares of Affimed in a report on Tuesday. HC Wainwright downgraded shares of Affimed from a “buy” rating to a “neutral” rating in a report on Wednesday. Wells Fargo & Company reiterated an “equal weight” rating and issued a $0.10 price objective (down from $11.00) on shares of Affimed in a report on Tuesday. StockNews.com initiated coverage on Affimed in a research note on Sunday, May 11th. They set a “sell” rating for the company. Finally, Leerink Partnrs cut Affimed from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.90.

Affimed Price Performance

AFMD opened at $0.09 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. The firm’s 50-day moving average price is $0.75 and its 200 day moving average price is $1.44. Affimed has a twelve month low of $0.07 and a twelve month high of $8.95.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Affimed stock. Intellectus Partners LLC increased its stake in Affimed (NASDAQ:AFMD) by 34.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,414 shares of the biopharmaceutical company’s stock after acquiring an additional 32,053 shares during the period. Intellectus Partners LLC owned approximately 0.79% of Affimed worth $150,000 at the end of the most recent reporting period. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.